PHCL 412 Exam 1 2026/2027 – 150+ Questions & Answers, Pharmacokinetics, Pharmacodynamics, ANS, Antidepressants, AEDs, Cardiovascular, Antimicrobials & Cancer Drugs

This PHCL 412 Exam 1 2026/2027 study resource is a comprehensive 50-page pharmacology exam review containing 150+ questions and answers covering foundational and clinically applied pharmacology. Major topics include pharmacodynamics, pharmacokinetics, drug-receptor interactions, ADME, autonomic pharmacology, antidepressants, antiepileptic drugs, cardiovascular pharmacology, over-the-counter medications, antiviral and antibacterial agents, analgesics, and cancer chemotherapy. The opening section also reviews the history and development of pharmacology, including Hippocrates, Galen, Paracelsus, William Withering, Friedrich Sertürner, Rudolph Buchheim, Oswald Schmiedeberg and Claude Bernard. The pharmacodynamics and receptor pharmacology section explains how drugs interact with receptors and effectors to alter cellular activity. Students review receptor conformational states, induced fit, agonists, partial agonists, antagonists and inverse agonists alongside the clinically important distinctions among affinity, efficacy, potency and selectivity. Quantitative concepts include saturation radioligand binding, Kd, Bmax, Ki, IC50 and EC50/ED50, as well as competitive versus noncompetitive antagonism. These topics provide the conceptual foundation for understanding dose-response relationships and why therapeutic and adverse effects can arise from interactions with intended and unintended molecular targets. The guide gives extensive attention to pharmacokinetics and ADME—absorption, distribution, metabolism and excretion. Students examine routes of drug administration, passive diffusion, active transport, Fick's law, bioavailability, pKa and pH-dependent ionization, ion trapping, plasma-protein binding, the blood-brain barrier and volume of distribution. Drug metabolism is divided into Phase I and Phase II reactions, with substantial emphasis on cytochrome P450 enzymes, particularly CYP3A4, enzyme induction and inhibition, drug interactions and enterohepatic circulation. The material also considers sex-related differences in body composition, organ function, metabolism and pharmacokinetic behavior. A major neuropharmacology component covers depression and antidepressant medications. Students review the biogenic amine hypothesis and the roles of serotonin, norepinephrine and dopamine before comparing SSRIs, SNRIs, tricyclic antidepressants, MAO inhibitors, atypical antidepressants and lithium. Specific medications include citalopram, fluoxetine, sertraline, venlafaxine, duloxetine, amitriptyline, doxepin and imipramine. High-yield safety concepts include serotonin syndrome, tricyclic antidepressant adverse effects, MAOI interactions with tyramine-containing foods, hypertensive crisis, lithium renal elimination and lithium-associated nephrogenic diabetes insipidus. The antiepileptic drug (AED) section connects seizure physiology with drug mechanisms. Students review strategies for decreasing neuronal excitability through voltage-gated sodium-channel blockade, calcium-channel modulation, increased GABAergic transmission and decreased glutamatergic signaling. Drugs covered include carbamazepine, oxcarbazepine, lamotrigine, phenytoin, topiramate, valproate, zonisamide, ethosuximide, gabapentin, pregabalin, levetiracetam, felbamate, tiagabine, benzodiazepines, barbiturates and vigabatrin. Important adverse effects and clinical considerations include Stevens-Johnson syndrome/toxic epidermal necrolysis, valproate-associated hepatotoxicity and fetal abnormalities, and the nonlinear pharmacokinetics and toxicity of phenytoin. The autonomic nervous system pharmacology portion examines sympathetic, parasympathetic and enteric regulation and the neurotransmitters acetylcholine, norepinephrine and epinephrine. Students compare alpha-1, alpha-2, beta-1 and beta-2 adrenergic receptors, including phenylephrine, prazosin, clonidine, dobutamine, metoprolol and albuterol. Cholinergic pharmacology includes nicotinic and muscarinic receptors, methacholine, carbachol, bethanechol, pilocarpine, neostigmine, physostigmine, atropine, scopolamine and ipratropium. The material also covers muscarinic toxicity patterns, nicotinic overdose and the physiological effects of autonomic signaling on blood vessels, the heart, lungs and eyes. Cardiovascular pharmacology includes hypertension, dyslipidemia, coronary disease and major antihypertensive drug classes. Students review hypertension risk factors and complications, lifestyle interventions, statins and HMG-CoA reductase inhibition, aspirin, thiazide diuretics, ACE inhibitors, ARBs, calcium-channel blockers, beta blockers, vasodilators, central sympathetic agents and aldosterone antagonists. The guide connects drug mechanisms with adverse effects such as ACE-inhibitor-associated cough, thiazide-associated hypokalemia, gout and glucose intolerance, while also discussing characteristics associated with increased statin toxicity. The OTC and analgesic pharmacology section reviews acetaminophen, aspirin, ibuprofen, naproxen, antihistamines, nasal decongestants, guaifenesin and dextromethorphan. Students study cyclooxygenase and prostaglandin physiology, analgesic and antipyretic effects, platelet inhibition, gastrointestinal toxicity, acetaminophen-associated hepatotoxicity and the use of N-acetylcysteine in acetaminophen overdose. The document also discusses misuse potential associated with some OTC preparations and reinforces that nonprescription status does not mean a medication is risk-free. A detailed antiviral and antibacterial pharmacology section addresses viral replication and major therapeutic targets. Topics include HIV entry and replication, CCR5/CD4 interactions, reverse transcriptase, integrase and protease inhibition; herpesvirus treatment with acyclovir; influenza neuraminidase inhibition; and selected therapies discussed for hepatitis and COVID-19. Antibacterial content covers beta-lactams, bacterial resistance mechanisms, macrolides, aminoglycosides, tetracyclines, fluoroquinolones and sulfonamides, including their actions on cell-wall synthesis, bacterial ribosomes, DNA gyrase and folate metabolism. MRSA, the mecA resistance mechanism and vancomycin are also included. The final portion introduces cancer pharmacology and chemotherapy. Students review antimetabolites, alkylating agents, natural products, hormones and antagonists, monoclonal antibodies and targeted therapies. Specific examples include mitomycin, R-CHOP therapy for non-Hodgkin lymphoma, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, tyrosine kinase inhibitors and trastuzumab (Herceptin). The material connects these therapies with oncogenes, growth-factor receptors, tumor-suppressor genes such as p53, Rb and PTEN, cancer-cell signaling, clonal expansion, metastasis, combination chemotherapy and mechanisms of drug resistance. For academic cross-reference, the material corresponds closely with established pharmacology references such as Katzung's Basic & Clinical Pharmacology and Goodman & Gilman's The Pharmacological Basis of Therapeutics, particularly their coverage of pharmacokinetics, pharmacodynamics, autonomic drugs, CNS pharmacology, cardiovascular agents, antimicrobial chemotherapy and antineoplastic drugs. These texts are appropriate references for verifying mechanisms and expanding on the exam material. Students should cross-check course-specific answers against their assigned edition and current clinical guidance because some statements in the uploaded study guide simplify complex pharmacology, contain terminology errors, or may reflect older treatment recommendations. This resource is especially relevant for PHCL 412 students, pharmacology students, pharmacy students, nursing and BSN students, medical students, physician-assistant students, allied-health students and other learners preparing for pharmacology examinations. It is particularly useful for students who need a broad review of receptor pharmacology, ADME, drug metabolism, autonomic drugs, antidepressants, antiepileptics, antihypertensives, statins, analgesics, antimicrobials, antivirals and chemotherapy. The uploaded document does not identify a specific institution, so University Not Specified is used rather than attributing the material to an unsupported university. Keywords: pharmacology Exam 1, pharmacology questions and answers, pharmacology study guide, pharmacodynamics, pharmacokinetics, ADME pharmacology, drug absorption, drug distribution, drug metabolism, drug excretion, receptor pharmacology, agonist antagonist, partial agonist, inverse agonist, drug potency, drug efficacy, drug affinity, EC50, IC50, Kd pharmacology, bioavailability, volume of distribution, cytochrome P450, CYP3A4, autonomic pharmacology, sympathetic nervous system drugs, parasympathetic drugs, adrenergic receptors, cholinergic receptors, alpha 1 receptor, alpha 2 receptor, beta 1 receptor, beta 2 receptor, antidepressant pharmacology, SSRI pharmacology, SNRI pharmacology, tricyclic antidepressants, MAO inhibitors, serotonin syndrome, lithium pharmacology, antiepileptic drugs, seizure pharmacology, phenytoin, carbamazepine, valproate, ethosuximide, benzodiazepines, GABA pharmacology, hypertension pharmacology, antihypertensive drugs, statins pharmacology, ACE inhibitors, ARBs, beta blockers, calcium channel blockers, thiazide diuretics, analgesic pharmacology, acetaminophen overdose, NSAID pharmacology, antiviral drugs, HIV pharmacology, acyclovir, antibacterial drugs, beta lactam antibiotics, macrolides, aminoglycosides, tetracyclines, fluoroquinolones, MRSA treatment, chemotherapy pharmacology, antineoplastic drugs, R CHOP chemotherapy, trastuzumab, tyrosine kinase inhibitors